Platform Development & Therapeutic Exploration

About Pencil Biosciences

Pencil Biosciences is an early-stage biotech developing a novel, synthetic RNA-guided gene editing platform positioned as an alternative to CRISPR-based systems. Its core innovation is a 'break-free' editing mechanism that avoids creating double-strand DNA breaks, potentially reducing off-target effects and expanding editable genomic sites. The company, which is privately held and pre-revenue, has secured initial grant and venture funding to advance its platform towards therapeutic applications in oncology and genetic diseases. Leadership is bolstered by recent appointments including an experienced Chair of the Board.

Therapeutic Areas